Search

Your search keyword '"Cho, Hearn Jay"' showing total 424 results

Search Constraints

Start Over You searched for: Author "Cho, Hearn Jay" Remove constraint Author: "Cho, Hearn Jay"
424 results on '"Cho, Hearn Jay"'

Search Results

1. Determining Optimal Combination Regimens for Patients with Multiple Myeloma

2. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma

3. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

6. Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma

7. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma

9. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

12. A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma

13. Supplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

14. Supplementary Tables S1, S2, S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

15. Figure S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

16. Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

17. A Mathematical Model for Tumor–Immune Dynamics in Multiple Myeloma

21. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

23. P-043 Leveraging wearable devices for remote patient monitoring facilitate earlier CRS detection following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM): early results from an IIT

24. P-471 The MMRF cure cloud research study: a real-world longitudinal investigation of patient treatments and outcomes, including patient reported outcome (PRO) surveys

26. Supplementary Table TS1 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis

27. Supplementary Figure FS2 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis

28. Data from Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

29. Supplementary Table from Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

30. Data from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis

31. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

33. Data from Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma

34. Supplementary Figures S1-S3 from MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin

35. Supplementary Data from Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma

36. Supplementary Tables S1-S4 from Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma

37. Supplementary Figures S1-S11 from Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma

38. Data from Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma

39. Trial designs and endpoints for immune therapies in multiple myeloma

40. Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis

41. Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support

42. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients

44. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

47. The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma

48. A three gene signature predicts response to selinexor in multiple myeloma

Catalog

Books, media, physical & digital resources